Johnson & Johnson has begun late stage trials of hepatitis C drug TMC435 as a first line treatment for the …
Pepscan Therapeutics, the biotech firm focusing on protein mimicry technology has signed a deal with Tibotec. Netherlands-based Pepscan will use …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

